Gadeta announces significant progress in advancing pipeline and TEG platform development · Aim is to develop gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors· Ph1/2 update on lead product GDT002 as.
- Spin-out from University of Oxford built on a decade of world-leading research on blood cancers and breakthrough innovation in single-cell multi-omic.
- Spin-out from University of Oxford built on a decade of world-leading research on blood cancers and breakthrough innovation in single-cell multi-omic analysis by founders Professor Adam Mead
- Spin-out from University of Oxford built on a decade of world-leading research on blood cancers and breakthrough innovation in single-cell multi-omic.
/PRNewswire/ ONA Therapeutics ("ONA"), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism in order to.